141 related articles for article (PubMed ID: 21091042)
1. PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms.
Hoeller S; Walz C; Reiter A; Dirnhofer S; Tzankov A
Expert Opin Ther Targets; 2011 Jan; 15(1):53-62. PubMed ID: 21091042
[TBL] [Abstract][Full Text] [Related]
2. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene.
Bousquet M; Quelen C; De Mas V; Duchayne E; Roquefeuil B; Delsol G; Laurent G; Dastugue N; Brousset P
Oncogene; 2005 Nov; 24(48):7248-52. PubMed ID: 16091753
[TBL] [Abstract][Full Text] [Related]
3. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.
Reiter A; Walz C; Watmore A; Schoch C; Blau I; Schlegelberger B; Berger U; Telford N; Aruliah S; Yin JA; Vanstraelen D; Barker HF; Taylor PC; O'Driscoll A; Benedetti F; Rudolph C; Kolb HJ; Hochhaus A; Hehlmann R; Chase A; Cross NC
Cancer Res; 2005 Apr; 65(7):2662-7. PubMed ID: 15805263
[TBL] [Abstract][Full Text] [Related]
4. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
Smith CA; Fan G
Hum Pathol; 2008 Jun; 39(6):795-810. PubMed ID: 18538168
[TBL] [Abstract][Full Text] [Related]
5. Pathology of the bone marrow and spleen in a case of myelodysplastic/myeloproliferative neoplasm associated with t(8;9)(p22;p24) involving PCM1 and JAK2 genes.
Dargent JL; Mathieux V; Vidrequin S; Deghorain X; Vannuffel P; Rack K
Eur J Haematol; 2011 Jan; 86(1):87-90. PubMed ID: 21070368
[No Abstract] [Full Text] [Related]
6. JAK2 inhibition for the treatment of hematologic and solid malignancies.
Harry BL; Eckhardt SG; Jimeno A
Expert Opin Investig Drugs; 2012 May; 21(5):637-55. PubMed ID: 22493978
[TBL] [Abstract][Full Text] [Related]
7. Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
Dunlap J; Kelemen K; Leeborg N; Braziel R; Olson S; Press R; Huang J; Gatter K; Loriaux M; Fan G
Am J Clin Pathol; 2011 May; 135(5):709-19. PubMed ID: 21502425
[TBL] [Abstract][Full Text] [Related]
8. Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia.
Poitras JL; Dal Cin P; Aster JC; Deangelo DJ; Morton CC
Genes Chromosomes Cancer; 2008 Oct; 47(10):884-9. PubMed ID: 18618714
[TBL] [Abstract][Full Text] [Related]
9. Recent developments on JAK2 inhibitors: a patent review.
Kiss R; Sayeski PP; Keserũ GM
Expert Opin Ther Pat; 2010 Apr; 20(4):471-95. PubMed ID: 20205617
[TBL] [Abstract][Full Text] [Related]
10. Jak2: normal function and role in hematopoietic disorders.
Ihle JN; Gilliland DG
Curr Opin Genet Dev; 2007 Feb; 17(1):8-14. PubMed ID: 17208428
[TBL] [Abstract][Full Text] [Related]
11. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.
Najfeld V; Cozza A; Berkofsy-Fessler W; Prchal J; Scalise A
Exp Hematol; 2007 Nov; 35(11):1668-76. PubMed ID: 17976519
[TBL] [Abstract][Full Text] [Related]
12. Myeloproliferative disorders carrying the t(8;9) (PCM1-JAK2) translocation.
Bousquet M; Brousset P
Hum Pathol; 2006 Apr; 37(4):500; author reply 500-2. PubMed ID: 16564930
[No Abstract] [Full Text] [Related]
13. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates.
Patnaik MM; Knudson RA; Gangat N; Hanson CA; Pardanani A; Tefferi A; Ketterling RP
Eur J Haematol; 2010 Jun; 84(6):518-24. PubMed ID: 20331734
[TBL] [Abstract][Full Text] [Related]
14. The two faces of myeloproliferative neoplasms: Molecular events underlying lymphoid transformation.
Holroyd A; Cross NC; Macdonald DH
Leuk Res; 2011 Oct; 35(10):1279-85. PubMed ID: 21722956
[TBL] [Abstract][Full Text] [Related]
15. Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F.
Gibson SE; Schade AE; Szpurka H; Bak B; Maciejewski JP; Hsi ED
Hum Pathol; 2008 Jul; 39(7):1111-4. PubMed ID: 18479730
[TBL] [Abstract][Full Text] [Related]
16. JAK2 and MPL mutations in myeloproliferative neoplasms.
Koppikar P; Levine RL
Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
[TBL] [Abstract][Full Text] [Related]
17. JAK the trigger.
Mahon FX
Oncogene; 2005 Nov; 24(48):7125-6. PubMed ID: 16007127
[TBL] [Abstract][Full Text] [Related]
18. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
Dawson MA; Curry JE; Barber K; Beer PA; Graham B; Lyons JF; Richardson CJ; Scott MA; Smyth T; Squires MS; Thompson NT; Green AR; Wallis NG
Br J Haematol; 2010 Jul; 150(1):46-57. PubMed ID: 20507304
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic mechanisms in myeloproliferative disorders.
Delhommeau F; Pisani DF; James C; Casadevall N; Constantinescu S; Vainchenker W
Cell Mol Life Sci; 2006 Dec; 63(24):2939-53. PubMed ID: 17131059
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals.
Wang YL; Lee JW; Kui JS; Chadburn A; Cross NC; Knowles DM; Coleman M
Acta Haematol; 2007; 118(4):209-14. PubMed ID: 18032883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
